Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
NAPIGEN is a biotechnology company focused on genome editing, specifically in mitochondrial engineering. The company develops innovative solutions aimed at enhancing food supply by creating hybrid crop plants with significantly improved yields. By producing robust male sterile lines, NAPIGEN offers advantages over traditional lines, ensuring stability and elite genetic backgrounds. This technology facilitates the development of non-GM hybrid seeds for crops that are primarily non-hybrid, such as wheat. Additionally, NAPIGEN's expertise extends to the genome engineering of various organisms, including plants, microbes, and animals, by targeting mitochondria and chloroplasts, which are essential for energy production in cells. The company's advancements are designed to meet societal needs and promote public acceptance of its biotechnological innovations.
Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated the best-in-class platform and initiated multiple programs across different disease areas.
Indapta Therapeutics is a privately held biotechnology company focused on developing a natural killer (NK) cell therapy platform aimed at treating both blood and solid tumor cancers. The company specializes in a proprietary off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the effectiveness of antibody therapies. Through its innovative approach, Indapta Therapeutics seeks to provide healthcare providers with advanced treatment options for patients suffering from cancer, leveraging the potent antibody-dependent cellular cytotoxicity (ADCC) activity of its NK cell therapy.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, dedicated to the research, development, and commercialization of innovative medicines for infectious diseases. Incorporated in 2017, the company is currently focused on its lead product candidate, epetraborole, a once-daily oral treatment aimed at addressing chronic non-tuberculous mycobacterial lung disease, a condition with significant unmet medical needs. AN2 Therapeutics is also involved in strategic partnerships, notably with Brii Biosciences, to enhance its development capabilities and reach. The company’s commitment is to leverage modern biomedical expertise to deliver transformational therapies for patients suffering from serious infections.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Nodexus is a biotech startup focused on providing accessible solutions for live single-cell isolation, targeting the industrial, biopharma, clinical research, and academic sectors. The company has developed the NX One platform, which features a low-cost hardware system complemented by single-use disposable microfluidic cartridges. This system is designed for various applications, including gene editing, cell line and antibody development, and studies on tumor heterogeneity. By offering affordable automated cell isolation, Nodexus aims to enhance biological workflows and extend the availability of advanced research tools to a broader range of clients.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
NanoMosaic specializes in innovative solutions for early illness detection, prognostic monitoring, and biomarker identification. The company has developed a unique platform that utilizes nanoneedles for protein detection and quantification. This technology facilitates the analysis of multiple biomarkers on a single chip, making it possible for the medical and healthcare sectors to enhance the speed and accuracy of biomarker discovery and validation. By enabling more efficient proteomic analysis, NanoMosaic aims to improve early disease detection and monitoring, ultimately contributing to better health outcomes.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.
Sydnexis specializes in developing a proprietary treatment for pediatric progressive myopia, addressing a significant global medical need. The company manufactures a topical eyedrop formulation aimed at treating this condition in children, allowing healthcare professionals to effectively manage and reduce the progression of myopia. Through its innovative approach, Sydnexis seeks to enhance eye care for pediatric patients and mitigate the prevalence of eye disorders in this demographic.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
New Equilibrium Biosciences focuses on the research and development of therapeutic drugs aimed at treating cancer, neurodegenerative diseases, and other medical conditions. The company specializes in targeting intrinsically disordered proteins (IDPs), which play a significant role in various disorders. By integrating artificial intelligence with quantum chemistry, New Equilibrium leverages biophysical experiments to explore opportunities for structure-based drug design. This approach includes the creation of compound libraries specifically for IDPs, allowing for the identification of potential drug candidates that can interact with transient binding pockets on these proteins. Through its innovative platform, New Equilibrium aims to enhance drug discovery processes and improve treatment options within the healthcare sector.
Graphite Bio is a gene editing company focused on targeted DNA integration to address severe diseases. The company employs technology that enables the insertion of new genetic sequences to replace defective genes, repair damaged portions of genes, and insert therapeutic genetic material at specific locations within the genome. This precise approach leverages natural cellular DNA repair mechanisms to enhance the efficiency of gene integration, aiming to correct the underlying causes of various diseases. Founded in 2019 and based in South San Francisco, California, Graphite Bio was previously known as Integral Medicines, Inc. and rebranded in August 2020. The company is committed to advancing gene replacement therapies and potential cures for individuals affected by serious health conditions.
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.
Locanabio, Inc. develops RNA-targeted gene therapies to treat a spectrum of underserved diseases. It offers therapies for neuromuscular, neurodegeneration, and ophthalmology diseases. Locanabio, Inc. was formerly known as Locana, Inc. and changed its name to Locanabio, Inc. in July 2020. The company was founded in 2016 and is based in San Diego, California.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations.
The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Saniona is a research and development company with low burn rate, a world class team and high ambitions.
Novavax, Inc. is a late-stage biotechnology company based in Gaithersburg, Maryland, that specializes in the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. The company’s lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, which targets seasonal influenza in older adults. Both of these candidates utilize the proprietary Matrix-M adjuvant to enhance immune responses. Novavax is also advancing a vaccine for RSV targeting older adults and children, as well as a candidate against the Ebola virus and a combination vaccine for influenza and RSV. Additionally, the company has initiated the development of a COVID-19 vaccine candidate, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company. Established in 1987, Novavax aims to address urgent global health needs through its innovative vaccine technologies.
Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer treatment. Founded in 2015 and headquartered in South San Francisco, California, Nkarta aims to enhance the efficacy and tolerability of cell therapies, addressing both hematologic and solid tumor malignancies. The company's approach utilizes chimeric antigen receptors on NK cells, enabling them to recognize and attack tumor cells more effectively. Nkarta's lead product candidates include NKX101, designed to harness innate NK cell biology for cancer detection and destruction, and NKX019, targeting the CD19 antigen to treat various B cell malignancies. By leveraging its NK expansion platform and proprietary cell engineering technologies, Nkarta seeks to provide a more potent and accessible treatment option, capitalizing on the natural ability of NK cells to identify and eliminate abnormal cells while minimizing side effects typically associated with other therapies.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, that specializes in developing innovative protein therapeutics through synthetic biology. The company focuses on creating novel cytokine Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead candidate, THOR-707, is a modified version of recombinant human IL-2 being tested for various solid tumors, both as a monotherapy and in combination with immune checkpoint inhibitors. Additionally, Synthorx is developing Synthorins for other indications, including IL-10 for immuno-oncology and IL-15 as an immunoregulatory cytokine. The company leverages proprietary engineered organisms to produce these advanced proteins with high fidelity, enhancing their efficacy, safety, and convenience for patients. Founded in 2014 with technology licensed from The Scripps Research Institute, Synthorx has attracted investment from various venture capital firms and operates as a subsidiary of Sanofi.
TeraPore Technologies, Inc. is a company based in South San Francisco, California, that specializes in developing membrane technology aimed at improving bioprocessing applications. Founded in 2013, TeraPore focuses on the purification of biological fluids through innovative solutions that combine uniform pores with high pore densities. This technology enables efficient and rapid purification processes, particularly for high-value products. By offering targeted and uniform nanofiltration capabilities, TeraPore addresses bioseparation challenges, providing biotech enterprises with membranes that exhibit desirable permeability, flow rates, and consistent pore sizes.
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
Sydnexis specializes in developing a proprietary treatment for pediatric progressive myopia, addressing a significant global medical need. The company manufactures a topical eyedrop formulation aimed at treating this condition in children, allowing healthcare professionals to effectively manage and reduce the progression of myopia. Through its innovative approach, Sydnexis seeks to enhance eye care for pediatric patients and mitigate the prevalence of eye disorders in this demographic.
Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, that specializes in developing innovative protein therapeutics through synthetic biology. The company focuses on creating novel cytokine Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead candidate, THOR-707, is a modified version of recombinant human IL-2 being tested for various solid tumors, both as a monotherapy and in combination with immune checkpoint inhibitors. Additionally, Synthorx is developing Synthorins for other indications, including IL-10 for immuno-oncology and IL-15 as an immunoregulatory cytokine. The company leverages proprietary engineered organisms to produce these advanced proteins with high fidelity, enhancing their efficacy, safety, and convenience for patients. Founded in 2014 with technology licensed from The Scripps Research Institute, Synthorx has attracted investment from various venture capital firms and operates as a subsidiary of Sanofi.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Nivalis Therapeutics is focused on developing innovative therapies aimed at treating cystic fibrosis (CF) by preserving intracellular S-nitrosoglutathione (GSNO), a molecule involved in cell signaling and implicated in the disease's pathophysiology. The company's lead candidate, N91115, specifically targets patients with the F508del mutation, the most prevalent mutation associated with CF. Founded in 2007 and headquartered in Boulder, Colorado, Nivalis Therapeutics is committed to improving the lives of individuals affected by cystic fibrosis and supporting their families through its research and development efforts.
SANUWAVE Health, Inc. is an emerging leader in the development and commercialization of a high- energy, focused, shock wave technology that is used in devices for the repair and regeneration of bones, muscles, tendons and skin, and for the separation of solids and fluid in non-medical systems. Within healthcare, SANUWAVE’s proprietary, patented Pulsed Acoustic Cellular Expression (PACE) technology emits high-energy, acoustic shock waves that restore the body’s normal healing processes. This activates biologic signaling which leads to tissue repair and regeneration and blood vessel growth – revascularization and microcirculatory enhancement. SANUWAVE has three devices that employ the PACE technology. The lead device for the global wound care market, dermaPACE®, is approved for use outside the United States (CE Marked) for advanced wound care indications and is currently being studied in a U.S-based supplemental pivotal clinical trial for diabetic foot ulcers. The orthoPACE® device is CE Marked for orthopedic and musculoskeletal indications. OssaTron®, the Company’s legacy device, is approved by the FDA for multiple orthopedic conditions which have failed to respond to conservative treatment. In addition, SANUWAVE has patented the use of its shock wave technology in non-medical fields, including energy (improved/enhanced oil recovery), water (purification), food (bacterial reduction), and industrial effluent (particulate separation), and is working toward licensing/partnership relationships.
CellScape Corporation (formerly Saryna Medical Corp) is a privately funded company headquartered in Newark, California, in the heart of the biotech corridor of the San Francisco Bay Area. The Company has developed whole fetal cell technology to transform prenatal genetic testing using a simple blood test. Their vision is to make comprehensive prenatal genetic testing available to every woman without requiring an invasive procedure that might put the fetus at risk. Their leadership team is accomplished in bringing innovative, cost-effective medical and molecular diagnostics to market.